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Abstract
Purpose: The purpose of this study is to illustrate the historical development of reirradiation during
several decades of the 20th century, in particular between 1920 and 1960.
Methods and materials: We chose the format of a narrative review because the historical articles
are heterogeneous. No systematic extraction of baseline data, treatment details, or follow-up care
was possible in many cases.
Results: Both hematological malignancies and solid tumors were treated with a second course of
radiation therapy, and indications included local relapse, regional nodal recurrence, and second
primary tumors developing in a previously treated region. The literature consists of retrospective
single-institution analyses describing treatment approaches that included external beam radiation
therapy, brachytherapy, or combinations thereof. Data on toxicities and survival were often
provided. Breast cancer and gynecological, head and neck, brain, and skin tumors are among the
entities included in this review.
Conclusions: The leading pioneers in the ﬁeld are fully aware of many of the challenges we
continue to debate today. These include the process of late tissue changes and development of
personalized treatment approaches and better ways to select patients who are likely to beneﬁt from
a second course of radiation therapy.
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Oncology. This is an open access article under the CC BY-NC-ND license (http://
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Introduction
Recent reviews and book chapters on reirradiation
have mostly focused on clinical and experimental data
from the past 25 to 30 years.1-9 This policy carries the risk
of disremembering long-term developments and the les-
sons learned from previous experience. Considering that
in the beginning of the 20th century, ionizing radiation
was often used to treat benign skin conditions, asthma,
and musculoskeletal disorders, which tend to recur, and
that treatment was far from standardized, repeat courses of
treatment were probably prescribed in the earliest years.
Of course, the dosimetric and technical limitations of
early equipment and regimens were also applied for the
treatment of malignant conditions, a setting necessitating
much higher radiation doses than benign diseases10;
therefore, in-ﬁeld and marginal relapse were common
problems.11,12 In the absence of effective alternatives, in
particular a lack of systemically administered anticancer
drugs and safe surgical salvage, reirradiation was some-
times prescribed for common hematological and solid
primary tumors. For this overview, the methodology,
outcomes, and side effects of reirradiation were extracted
from historical publications between 1920 and 1960 to
compare them with modern clinical practice. We chose
the format of a narrative review because the historical
articles were heterogeneous and differed in several as-
pects from today’s rigorously reviewed scientiﬁc litera-
ture. No systematic extraction of baseline data, treatment
details, or follow-up care was possible in many cases.
Methods
Historical articles were identiﬁed from PubMed; the
electronic archives of the British Journal of Radiology,
British Medical Journal, Strahlentherapie, Journal of the
American Medical Association, and California Medicine
and its predecessors; and by crosschecking the references
from already included articles and textbooks. The key
words “reirradiation,” “re-irradiation,” “repeat radio-
therapy,” “second radiotherapy,” “radiation retreatment,”
and “recurrent AND radiation therapy” were entered.
English and German language articles were included. Any
information a study provided about dose is described in
the Results section. Unfortunately, several of the included
studies provided no information about median dose or
exposure. Some included a detailed description only of
exemplary cases that the authors found particularly
instructive.
Results
Although the focus of this review was on solid tumors,
Desjardins reported a case of reirradiation of mediastinal
Hodgkin disease in the 1920s.13 In the treatment of
chronic myelogenous leukemia, irradiation increased the
duration of “efﬁcient life” (a rigorous deﬁnition of this
endpoint was not provided) by 30% (0.8 years), based on
82 cases reported in 1931.14 Most often, the spleen was
treated, and sometimes the spleen plus long bones.
Survival outcomes were comparable regardless of treated
volumes. Repeated cycles of low doses of radiation pro-
duced remarkable symptomatic improvement. The effect
lasted from a few months to a year.
In 1926, Lee and Tannenbaum reported their experi-
ence with more than 300 patients managed for recurrent
inoperable breast cancer at Memorial Hospital, New
York.15 The term inoperable referred to vastly different
scenarios, including but not limited to technically inop-
erable lymph node metastases and widespread distant
metastases. Roentgen rays, radium, or a combination of
both was used. Individualized or personalized oncology is
not a new idea, as reﬂected in the sentence “each patient is
a special problem to be handled in a special way.”15 Lee
and Tannenbaum also cited references from different
countries, all of which demonstrated that reirradiation
could be prescribed (eg, after failure of what was called
prophylactic irradiation [postoperative adjuvant radiation
therapy]). There was controversy in the literature
regarding the usefulness of this approach, because some
authors regarded recurrent tumors as not sufﬁciently
radiosensitive to warrant further treatment.16 Lee and
Tannenbaum did not provide separate results for reirra-
diated patients. According to their general conclusion,
radiation therapy for recurrent breast cancer prolonged the
life of their patients and may have controlled the disease
for a considerable number of years. Irradiation was used
during later decades as well,17 but, unfortunately, detailed
outcome data were not reported.
For cervical cancer, radiation therapy had become an
accepted treatment well before the Second World War. In
describing their approach at the Los Angeles Tumor
Institute, California, from 1930, Soiland and Costolow
mentioned that “the duration of the ﬁrst application is
twenty-eight hours and the second application twenty-
four hours, the radium being applied against the cervix
and intrauterine at the same time.”18 “Following this, no
further radium should be given for from six to twelve
months. The patient is observed at monthly intervals, and
late recurrences, appearing a year or so after the original
treatment, are often treated with small doses of radium
applied locally, although great care is exercised. Often,
suspicious thickened areas remain for several months and
ﬁnally disappear.” This policy emphasizes a crucial point
in decision making, namely to conﬁrm the presence of
active tumor before prescribing further treatment.
According to Healy, of 1574 patients with cervical
cancer treated between 1918 and 1931 at Memorial
Hospital, New York, only 11% required further radiation
therapy.19 Only 2 of these patients survived more than 3
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years, leading Healy to conclude that “a lesion once fully
and adequately irradiated cannot again be treated to
advantage with radium or roentgen therapy. Irradiation
leads to tissue changes, largely in the nature of endarteritis
and ﬁbrosis, and further irradiation of such structures
results in the formation of indolent chronic ulcers and
sloughs, which are painful and extremely difﬁcult to
heal.” He also acknowledged tremendous interinstitu-
tional variations in treatment approaches.
In 1956, Murphy and Schmitz from Roswell Park
Memorial Institute, Buffalo, NY, reported on treatment of
failures following an apparently adequate course of ra-
diation for cervical cancer.20 They stated that “re-irradi-
ation is particularly justiﬁed when a curative surgical
approach would entail not only an appreciable mortality
risk but also a high degree of permanent disability. Tissue
changes resulting from previous radiotherapy do not
contraindicate re-irradiation if cure or palliation is
possible.” Between 1936 and 1941, 461 patients were
reirradiated, typically with combined radium and roent-
gen rays (brieﬂy reviewed in the article’s introduction
section, referred to as unpublished data). After reirradia-
tion, 20% of the patients lived 5 or more years without
clinical evidence of cancer. In the Murphy and Schmitz
paper, 46 patients with squamous cell cancer treated be-
tween 1946 and 1950 were reviewed. Patients were aged
31 to 70 years. Adequate treatment for 1 course consisted
of total doses of 7000 R and 4500 R to anatomical points
A and B located 2 and 5 cm lateral to the center of a
tandem intrauterine applicator (from roentgen rays and
radium). In 4 illustrative cases, treatment details including
technique and doses were provided. Nine patients (20%)
were alive at the time of reporting, with a maximum
follow-up of 8 years. The absolute 5-year survival with
no evidence of cancer was 16%. In fatal cases, the
average survival time was 13 months. The interval be-
tween the 2 courses was 4 to 89 months (median, 14).
The disease status was categorized as persistent if the
interval was short. Early and advanced stages were reir-
radiated, the latter being described as extrapelvic disease,
uremia, or lower limb edema. No apparent correlation
between the time interval and treatment outcome was
evident. Many patients experienced subjective and
objective palliation. Long-term survival was recorded
only in patients in good physical condition with limited
pelvic recurrence. Late complications in the 9 surviving
patients included chronic cystitis, chronic proctitis and
rectal bleeding, and rectovaginal ﬁstula (2 patients). All
patients were described as socially active and relatively
comfortable. Seven patients received a second
retreatment.
Garland and Sisson reported the results of irradiation
for lip, tongue, and ear cancer between 1932 and 1948
(San Francisco, CA).21 They observed that patients with
marginal recurrence, or recurrence after inadequate
dosage, may sometimes be cured by radical reirradiation.
Of 105 patients with lip cancer, 3 developed marginal
recurrences; these were reirradiated, and growth was
arrested. Three of 71 patients with tongue cancer were
treated for recurrent tumors after previous radiation
therapy. Regarding ear cancer, 1 of 25 patients was
treated for early relapse after previous radiation therapy,
and 1 more patient was reirradiated at a later time after
having been diagnosed with recurrence. No details about
the doses, time intervals, efﬁcacy, or toxicity were
reported.
Zuppinger reported the University of Zurich data with
protracted fractionated radiation therapy between 1931
and 1936 in 107 patients with head and neck tumors.22 Of
these, 13 (12%) were reirradiated (in 7 cases, after more
than 5 years; minimum interval, 5 months). Four patients
(31%) did not complete reirradiation. The reason for
treatment was local progression, nodal relapse, or a sec-
ond primary head and neck tumor. The same total dose as
in ﬁrst line was administered; however, overall treatment
time was longer for the second course. Toxicity included
need for tracheostomy and severe swallowing dysfunction
in a minority of patients. Nevertheless, Zuppinger
concluded that reirradiation is safe and promising unless
the patient suffers from an ulcerated laryngeal tumor. Two
years later, he published a larger series of 64 patients with
recurrent head and neck or thyroid cancer.23 Reirradiation
was given with 170 and 180 kV roentgen rays once or
twice daily over 5 to 6 weeks. The interval between the
series ranged from 3 months to 7 years. In some cases,
patients were followed for more than 5 years after reir-
radiation. The aim of treatment was symptom palliation in
9/64 patients (14%). Reirradiation was not completed as
prescribed in 11/64 patients (17%). Seven patients (11%)
died during treatment or within the ﬁrst month. Unsatis-
factory outcome was seen in patients with oral cavity and
hypopharynx tumors. These data suggest that patient se-
lection is challenging; however, reirradiation was often
feasible and sometimes successful in salvaging these
patients. Zöllner (Jena, Germany) performed a compre-
hensive study of radiation-induced complications after
treatment of laryngeal cancer, which included 3 patients
who developed fatal complications after reirradiation.24 In
1 case, soft-tissue necrosis and chondronecrosis resulted
in a fatal outcome after 6 courses of radiation therapy
(1 high dose, 5 low-moderate dose), which were admin-
istered between 1931 and 1934. Another patient died as a
result of pneumonia caused by laryngeal dysfunction after
3 courses of radiation therapy (1935-1937). The third
patient died from soft-tissue necrosis, chondronecrosis,
and osteomyelitis after 5 courses of radiation therapy
(1933-1935).
Between 1940 and 1950, selected patients with naso-
pharyngeal malignancy were reirradiated at the University
of California School of Medicine, San Francisco.25 De-
tails regarding this early experience were reported by Fu
et al.26 Their analysis of 42 patients with different
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histological tumor types covered 1940 through 1974,
emphasizing that only few patients were eligible for this
approach. The time to reirradiation was in the range of
4 months to 9.5 years. External beam radiation therapy,
brachytherapy, or combination therapy was prescribed. In
contrast to earlier publications on head and neck
tumors,22,23 actuarial 5-year survival was reported (41%).
Survival was better when the disease-free interval
between ﬁrst diagnosis and recurrence was longer. Six
patients (14%) developed soft-tissue necrosis, and 3 (7%)
developed osteoradionecrosis (all minimally symptom-
atic). The authors’ preferred approach in patients with
local and/or nodal recurrence was surgery followed by
intracavitary radium therapy. For bulky, invasive lesions,
external beam radiation therapy was administered ﬁrst
(3000 R in 3 weeks).
Articles about reirradiation of the cranium and central
nervous system date back more than 80 years. For
example, Beclere and Levy included a few illustrative
cases treated before 1925 in their book chapter from
1931.27 Brain tumors of different locations were reirra-
diated, twice in selected cases. One of these patients
initially received subtotal resection for a cerebellar glioma
followed by mixed roentgen and radium therapy and was
treated with repeat radium therapy 6 years later. A
different patient received 3 courses of radiation therapy
between 1923 and 1926.28 She suffered from a symp-
tomatic brainstem tumor diagnosed by ventriculography;
her pressure-related symptoms improved in 1923 and
1925, but not after the last treatment attempt in 1926. She
died shortly after, and autopsy showed psammoma. Her
tumor most likely belonged to the group of meningeal
neoplasms, but details were not reported. The same holds
true for radiation doses; it was only mentioned that the
doses were identical for each of the courses. A different
textbook mentioned 16 patients, mainly with glioma, 2 of
whom were reirradiated after intervals of 6 and 12
months, respectively.29 Neither histology nor treatment
details were communicated for these 2 patients; however,
the author acknowledged the challenges of establishing
correct radiologic and tissue diagnoses and the possibility
of erroneous diagnoses, especially if autopsy was not
performed after the patients’ demise.
Ramsay reported that, from 1955 to 1958, 100 pa-
tients with metastatic carcinoma of the breast were
treated by implantation of the pituitary, an endocrine
manipulation in an era when effective drugs for this
purpose were lacking.30 Gold was used in 54 cases and
yttrium in 36. The remaining 10 patients had ﬁrst 1 and
later the other isotope implanted. Of greater relevance is
the publication by Chu and Hilaris from Memorial
Hospital, New York, about brain metastases, which
covers 1954 to 1958.31 The typical dose prescription
was 3000 R in 3 weeks. Selected patients (n Z 17)
received repeat whole-brain radiation therapy. Twelve
(71%) were categorized as favorable responders and
survived for 8 months on average. Patients who failed
to respond survived for 1.4 months on average. No
clinical evidence of damage to normal brain tissue was
seen. Three patients received 3 courses. In a compara-
ble retrospective study by Shehata et al, 81 patients
with lung, breast, and other primary tumors treated with
whole-brain radiation therapy were included.32 Of these,
35 (43%) were retreated, 12 were retreated twice, and 3
patients received 4 courses. In 68%, a single dose of 10
Gy was given; other patients received a short course of
less than a week (2-5 fractions). Time interval,
fractionation details, and cumulative doses were not
reported. A patient with non-small cell lung cancer who
received 4 courses over a 20-month period (total dose,
74 Gy) experienced a clinical response each time and
survived for more than 2 years. A clinical beneﬁt was
reported after the ﬁrst, second, and third courses in
69%, 68%, and 50% of the patients, respectively. Mean
duration of improvement was 1.8, 2.6, and 1.5 months,
respectively.
In a textbook from 1965, Kramer provided a sum-
mary of the knowledge about reirradiation, including
persistent, recurrent, and new primary tumor scenarios.33
Factors to consider during decision making included the
natural history of the tumor, its extent, the condition of
the normal tissues, the details of the previous treatment,
and the objective of the proposed reirradiation. He rec-
ommended that “an attempt must be made to determine
whether the initial course of therapy has failed because
of inadequate doses, geographical miss, or radio-
resistance of the tumor. Previously irradiated tissues are
compromised a priori to some extent, whether this is
clinically obvious or not.” He advocated radium needle
implants as the ﬁrst choice in certain accessible sites. In
his practice at Jefferson Medical College Hospital,
Philadelphia, PA, 63 patients were reirradiated between
1956 and 1960. Of these, 8 (13%) were treated with
curative intent, including 6 with head and neck squa-
mous cell cancer. The median interval was 3 years
(18 months-12 years). Six patients were treated by cobalt
beam and 2 by implants. The cumulative total doses
were not reported. Two patients failed locally. Another 2
patients developed necrosis. He considered reirradiation
worthwhile in 7 patients. Fifty-ﬁve patients (87%)
received palliative reirradiation. The largest subgroups
had cervix, uterus, and head and neck cancers; other
sites included lung, breast, large bowel, and brain. In 27
cases (49%), reirradiation was given within 1 year. Most
patients received a minimum tumor dose of 3500 R in 2
to 3 weeks. In 24 patients (44%), reirradiation was
worthwhile, in 11 doubtful (20%), and in 20 useless
(36%). The results were better when the interval excee-
ded 1 year. In 8 patients, a major degree of necrosis
appeared (5 vesicovaginal or rectovaginal ﬁstula), in 1
case causing a fatal hemorrhage. He concluded that
“there is a deﬁnite place for re-irradiation, but patients
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must be selected most carefully if useless therapy is to
be avoided.”
Discussion
In contrast to the historical 20th century reirradiation
studies reviewed here, modern radiation therapy is pre-
ceded by meticulous tissue diagnosis and staging with
lower probability of diagnostic error and has a very
different workﬂow and technological basis, characterized
by advanced 3- or 4-dimensional imaging, functional
imaging, 3-dimensional treatment planning, image guided
or stereotactic localization and veriﬁcation, intensity
modulated beams, and volumetric modulated arcs.34-42
Recent developments also include new isotopes for
brachytherapy, updated recommendations for dose pre-
scription, the introduction of proton and carbon ion
beams, and integration of systemic agents and hyper-
thermia that modify the radiation response.43-49 In addi-
tion to retrospective analyses, many prospective studies
have been performed since 1990,50-55 including random-
ized phase 2 and 3 trials.56-61 As a consequence, reirra-
diation has become part of clinical practice
guidelines.62,63 In addition to common indications, pre-
liminary evidence in other areas has started to emerge (eg,
esophageal cancer, soft-tissue sarcoma).44,64 Statistical
methods and toxicity scoring have evolved as well.
Patient-reported outcomes have not been included in any
of the historical studies. When activities of daily living
and clinical symptoms were reported, these were
physician-assessed. Terms such as “efﬁcient life, socially
active” or “relatively comfortable” were used to describe
patients’ lives. Data presentation was often incomplete,
emphasizing that the process of manuscript peer review
and correction has also changed. Because these limita-
tions and the paucity of high-quality data, a narrative
review format was chosen.
Reirradiation for symptom palliation was effective for
hematological malignancies and breast, cervical, head and
neck, brain, and lung tumors, among others. Radiation
doses were not always reported; however, most authors
prescribed doses in ranges that we still use today (eg,
3500 R [35 Gy] in 2-3 weeks).33 Survival beyond 1
year was uncommon. Toxicity was not a major concern;
however, occasional patients developed severe
complications such as necrosis and ﬁstula. The cumula-
tive total doses for these patients were not systematically
calculated. Because of less advanced imaging and lack of
coregistration and deformable algorithms, the exact vol-
ume of overlap between 2 courses was almost impossible
to quantify. Dose-effect calculations and normal tissue
dose constraints emerged more recently and continue to
evolve.2,6,40,51 Animal experiments that improved our
understanding of tissue recovery also were not available
during the early decades.65-67
It was, and is still today, less common to reirradiate with
curative aim (13% according to Kramer33). According to
Zuppinger, 12% of patients with head and neck cancer were
reirradiated, many with curative doses.23 Both authors re-
ported a certain probability of local control and 5-year
survival, but also severe toxicity. This was also
conﬁrmed by Stevens et al, who used more modern tech-
nology in 100 patients treated with curative intent from
1964 to 1991.68 This group required intact and non-
ulcerated mucosal surfaces and no more than minimal
visible or palpable late effects from the prior irradiation. At
least one-third of patients evaluated were not accepted for
reirradiation. In 82 patients, external beams only were used
(1.8-2 Gy per day, 5 days per week, planned dose at least 50
Gy). Thirty-two patients received cumulative external ra-
diation doses greater than 120 Gy. Median follow-up was
longer than 3 years. Actuarial 5-year survival was 17% in
case of recurrent and 37% in case of new primary tumors.
Nine patients (9%) developed severe late reactions,
including 4 deaths from hemorrhage. In an accompanying
editorial, C.C. Wang emphasized, among other points, that
tumorsmust be small and superﬁcial and the regionmust be
free from excessive chronic radiation changes and ﬁbrosis
if one attempts 60 to 70 Gy reirradiation.69 He also pointed
out that “experience has shown that indiscriminate use of
high dose re-irradiation often makes a bad matter worse.”
Regarding cervical cancer, the absolute 5-year survival
with no evidence of cancer was 16%.20 Long-term survival
was recorded only in patients with limited pelvic recurrence
in good physical condition. Late complications in the 9
surviving patients included chronic cystitis, chronic proc-
titis and rectal bleeding, and rectovaginal ﬁstula. In many,
but not all, studies, better results were observed when the
time interval between initial and reirradiation was longer;
however, there was controversy in the literature regarding
the usefulness of this approach because some authors
Table 1 Reasons for reirradiation
Dose required to achieve permanent local control was unknown
Dose required to achieve permanent local control could not be administered because of technical limitations and lack of
radiosensitizing agents
Correct stage and target volume could not be deﬁned because of imaging limitations
Development of second primary tumors
Need for repeated symptom palliation
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regarded recurrent tumors as not sufﬁciently radiosensitive
towarrant further treatment, whereas others stated that there
is a deﬁnite place for reirradiation. Many authors
acknowledged tremendous interinstitutional variations in
treatment approaches, which often developed based on
personal education and experience rather than scientiﬁc
evidence. Table 1 summarizes some of the reasons that may
have necessitated reirradiation in the early 20th century.
It is important to remember that the leading pioneers in the
ﬁeldwere fully aware ofmany of the challenges that continue
to be debated today. These include the process of late tissue
changes (underlyingmechanisms,mitigation, and treatment),
development of personalized treatment approaches, and bet-
terways to select patientswhoare likely to beneﬁt.15,19,22,33,70
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